Compare Neurocrine Biosciences Inc (NBIX) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nike Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Nike Inc trades at $42.96 (market cap $64.49B). The key difference: Nike Inc is far larger — about 3.7× Neurocrine Biosciences Inc's market cap, and Nike Inc pays a 3.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NKE | |
|---|---|---|
Market Cap | $17.40B | $64.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $79.24 |
52-Week Low | $123.10 | $40.75 |
Enterprise Value | $16.49B | $66.49B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
